- Home
- CLLS vs SOPH Comparison
CLLS vs SOPH Comparison
Compare CLLS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SOPH
- Stock Information
- Founded
- CLLS 1999
- SOPH 2011
- Country
- CLLS France
- SOPH Switzerland
- Employees
- CLLS N/A
- SOPH 423
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- SOPH Health Care
- Exchange
- CLLS Nasdaq
- SOPH Nasdaq
- Market Cap
- CLLS 143.4M
- SOPH 219.8M
- IPO Year
- CLLS 2007
- SOPH 2021
- Fundamental
- Price
- CLLS $1.61
- SOPH $3.67
- Analyst Decision
- CLLS Buy
- SOPH Buy
- Analyst Count
- CLLS 1
- SOPH 1
- Target Price
- CLLS $4.00
- SOPH $7.00
- AVG Volume (30 Days)
- CLLS 52.1K
- SOPH 179.8K
- Earning Date
- CLLS 08-05-2025
- SOPH 08-05-2025
- Dividend Yield
- CLLS N/A
- SOPH N/A
- EPS Growth
- CLLS N/A
- SOPH N/A
- EPS
- CLLS N/A
- SOPH N/A
- Revenue
- CLLS $54,747,000.00
- SOPH $67,173,000.00
- Revenue This Year
- CLLS $48.52
- SOPH $16.07
- Revenue Next Year
- CLLS $5.17
- SOPH $22.94
- P/E Ratio
- CLLS N/A
- SOPH N/A
- Revenue Growth
- CLLS 351.26
- SOPH 4.66
- 52 Week Low
- CLLS $1.10
- SOPH $2.58
- 52 Week High
- CLLS $2.43
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- CLLS 61.29
- SOPH 69.36
- Support Level
- CLLS $1.56
- SOPH $2.81
- Resistance Level
- CLLS $1.49
- SOPH $3.40
- Average True Range (ATR)
- CLLS 0.09
- SOPH 0.30
- MACD
- CLLS 0.02
- SOPH 0.06
- Stochastic Oscillator
- CLLS 86.67
- SOPH 100.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.